Biogen

Biogen logo
🇺🇸United States
Ownership
Private
Established
1978-01-01
Employees
7.5K
Market Cap
$29.6B
Website
https://www.biogen.com
Introduction

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe

First Posted Date
2009-06-08
Last Posted Date
2009-06-08
Lead Sponsor
Biogen
Target Recruit Count
74
Registration Number
NCT00915577

Open-Label Safety Extension Study of Avonex

Phase 4
Completed
Conditions
Interventions
First Posted Date
2009-06-08
Last Posted Date
2009-06-08
Lead Sponsor
Biogen
Target Recruit Count
408
Registration Number
NCT00915460

Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers

Phase 4
Completed
Conditions
Interventions
First Posted Date
2009-06-04
Last Posted Date
2009-06-04
Lead Sponsor
Biogen
Target Recruit Count
121
Registration Number
NCT00913666

A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers

First Posted Date
2009-06-04
Last Posted Date
2009-06-04
Lead Sponsor
Biogen
Target Recruit Count
96
Registration Number
NCT00913250

Immunogenicity and Safety Study of Serum-Free Avonex

Phase 2
Completed
Conditions
Interventions
First Posted Date
2009-06-03
Last Posted Date
2009-06-10
Lead Sponsor
Biogen
Target Recruit Count
155
Registration Number
NCT00912860

Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802.

First Posted Date
2009-05-25
Last Posted Date
2017-10-30
Lead Sponsor
Biogen
Target Recruit Count
51
Registration Number
NCT00908154
Locations
🇬🇧

GSK Investigational Site, London, United Kingdom

Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis

First Posted Date
2009-05-21
Last Posted Date
2014-09-19
Lead Sponsor
Biogen
Target Recruit Count
1516
Registration Number
NCT00906399
Locations
🇬🇧

Research Site, Sheffield, United Kingdom

Effects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMS

First Posted Date
2009-04-20
Last Posted Date
2018-11-08
Lead Sponsor
Biogen
Target Recruit Count
195
Registration Number
NCT00884481
Locations
🇸🇪

Research Site, Örebro, Sweden

A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) Patients

First Posted Date
2009-03-30
Last Posted Date
2017-03-21
Lead Sponsor
Biogen
Target Recruit Count
224
Registration Number
NCT00871780
Locations
🇺🇦

Biogen Idec Investigative Site, Simferopol, Ukraine

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis

First Posted Date
2009-03-27
Last Posted Date
2016-08-30
Lead Sponsor
Biogen
Target Recruit Count
517
Registration Number
NCT00870740
Locations
🇬🇧

Research Site, Stoke-on-Trent, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath